Consensus on Testosterone treatment for postmenopausal women with hypoactive sexual desire dysfunction
The Endocrine Society and 10 other internationally esteemed medical societies have issued the first Global Position Statement on the use of Testosterone in the treatment of women.
It follows years of debate regarding Testosterone therapy for women and, for the first time, provides agreement among experts and medical societies about how Testosterone could be prescribed for women.
An international task force of Experts from leading medical societies, brought together by the International Menopause Society, produced the Global Position Statement to provide clear guidance regarding the prescribing and measurement of Testosterone for female Testosterone therapy as well as advice on Testosterone prescribing practices that have the potential to be ineffectual or cause harm.
They concluded that Testosterone can be effective at improving sexual wellbeing for postmenopausal women with hypoactive sexual desire dysfunction ( HSDD ).
Recognized benefits included improved sexual desire, arousal, orgasm and pleasure, together with reduced concerns and distress about sex.
HSDD is thought to affect around 32% of women at midlife; and, while it's common for women to lose interest in sex around the time of the menopause and after, the use of Testosterone as a treatment offers women an approach that may significantly improve their sexual and related emotional wellbeing. ( Xagena )
Source: The Endocrine Society, 2019